Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Comment by Stocktreeon Jul 20, 2016 1:08pm
121 Views
Post# 25069220

RE:What is 1 million EAA Screening Tests worth - Part 2

RE:What is 1 million EAA Screening Tests worth - Part 2
Great job again there MM. One of your best yet!
Love the style, but mostly the information density to the square inch ratio.
I don't always respond to your posts, mostly because there is often nothing to argue with or, in my case, I don't have what it takes to add to or to challenge your arguments, but I always enjoy diving into your analyses.

Two things I would like to ask you:

1- The promotion costs have been discussed here lately. Posters have argued that they will be quite large, as they usually are in the biomed sector. I do not understand why that would be the case however for an IC/ER treatment that will have the benediction of the FDA as the best option available to save lives/costs... We will not be playing adds on TV, the radio or in the media or raising awareness among the public. It should be mostly major medical professional conferences and information spreading to heads of IC units or am I completely in the ditch here? The costs shouldn't be  major burden in our case in my opinion, but I'd like your take on that.

2- I'm totally convinced about the great business opportunity (based on all numbers, conservative and realist, floating around) and I am also totally reassured about our approval chances (based on the company's most recent releases). But I'd like to know what is your gut feeling about how the real deal will play out. Something tells me we will benefit somewhat from our investment, but that we will not get what we will be rightfully owed. As this question/statement is not anchored in facts, don't bother getting into it if you don't like speculating on empty impressions.

Bullboard Posts